First Parkinson’s Patient Dosed with IkT-148009 in Phase 1 Trial

First Parkinson’s Patient Dosed with IkT-148009 in Phase 1 Trial

309966

First Parkinson’s Patient Dosed with IkT-148009 in Phase 1 Trial

The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009, an investigational oral therapy being developed by Inhibikase Therapeutics to slow or stop disease progression. “We are pleased to begin dosing patients in our Phase 1b study,” Milton Werner, PhD, Inhibikase‘s president and CEO, said in a press release. IkT-148009 is a small molecule that works by blocking the activity of Abelson tyrosine kinase, or c-Abl, a protein…

You must be logged in to read/download the full post.